Cargando…

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy

Emerging evidence suggests that the three tyrosine kinase inhibitors currently approved for the treatment of patients with chronic myelogenous leukemia (CML) – imatinib, dasatinib, and nilotinib – have potential cardiotoxic effects. The mechanisms behind these events, and the relations between them,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Zhenshu, Cang, Shundong, Yang, Ting, Liu, Delong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications 2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222244/ http://dx.doi.org/10.4081/hr.2009.e4

Ejemplares similares

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022)

The Bone Phenotype and Pain Response to Pamidronate in Tyrosine Kinase Inhibitor–Treated Chronic Myelogenous Leukemia
por: Lavoie, Declan C T, et al.
Publicado: (2019)

Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
por: Kaehler, Meike, et al.
Publicado: (2021)

P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
por: Cang, Shundong, et al.
Publicado: (2008)

Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia
por: Lei, Hu, et al.
Publicado: (2021)

A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors
por: Li, Qing, et al.
Publicado: (2016)

Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: Indian perspective
por: Ghosh, K
Publicado: (2022)

Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
por: Ono, Takaaki
Publicado: (2021)

Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells
por: Mitrovský, Ondřej, et al.
Publicado: (2023)

Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells
por: Okabe, Seiichi, et al.
Publicado: (2023)

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer
por: Cang, Shundong, et al.
Publicado: (2009)

Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
por: Okumura, Lucas M., et al.
Publicado: (2015)

Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells
por: Hirao, Takuya, et al.
Publicado: (2017)

Myelomastocytic Blast Cell Crisis in Resistant Tyrosine Kinase Inhibitor Chronic Myelogenous Leukemia: Case Report and Review of Literature
por: Martinez-Cordero, Humberto, et al.
Publicado: (2019)

Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: A single center experience
por: Bommannan, KB, et al.
Publicado: (2022)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib
por: Cassuto, Ophélie, et al.
Publicado: (2012)

Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
por: Chen, Z, et al.
Publicado: (2016)

Extramedullary Involvement by Chronic Myelogeneous Leukemia in Five Patients With Unusual Clinicopathologic Features: A Review of the Effectiveness of Tyrosine Kinase Inhibitors
por: Soni, Abha, et al.
Publicado: (2016)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients
por: Rivera, Donna R, et al.
Publicado: (2020)

Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia
por: Kim, Lisa, et al.
Publicado: (2021)

Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia
por: Janani, Gopalarethinam, et al.
Publicado: (2023)

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
por: Wang, Shuhang, et al.
Publicado: (2016)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
por: Martinelli, Giovanni, et al.
Publicado: (2009)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

Predicting individual-specific cardiotoxicity responses induced by tyrosine kinase inhibitors
por: Shim, Jaehee V., et al.
Publicado: (2023)

Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
por: Long, Bing, et al.
Publicado: (2011)

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
por: Parikh, Kaushal, et al.
Publicado: (2014)

Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
por: DeAngelo, D J
Publicado: (2012)

Chronic myelogenous leukemia in ulcerative colitis
por: Katsanos, Konstantinos H., et al.
Publicado: (2011)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Atypical Presentation of Chronic Myelogenous Leukemia
por: Updyke, Katelyn Mariko, et al.
Publicado: (2017)

Inhibition of abl Oncogene Tyrosine Kinase Induces Erythroid Differentiation of Human Myelogenous Leukemia K562 Cells
por: Honma, Yoshio, et al.
Publicado: (1990)

Novel CD20 monoclonal antibodies for lymphoma therapy
por: Cang, Shundong, et al.
Publicado: (2012)

Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation
por: Sestier, Maude, et al.
Publicado: (2021)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tgbrcr3nkglrhms6h4bsgarpaq